174 related articles for article (PubMed ID: 22948532)
1. Abnormal function of monoamine oxidase-A in comorbid major depressive disorder and cardiovascular disease: pathophysiological and therapeutic implications (review).
Machado-Vieira R; Mallinger AG
Mol Med Rep; 2012 Nov; 6(5):915-22. PubMed ID: 22948532
[TBL] [Abstract][Full Text] [Related]
2. Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [11C]-harmine PET study.
Sacher J; Houle S; Parkes J; Rusjan P; Sagrati S; Wilson AA; Meyer JH
J Psychiatry Neurosci; 2011 Nov; 36(6):375-82. PubMed ID: 21463543
[TBL] [Abstract][Full Text] [Related]
3. Effect of MAO-B inhibition against ischemia-induced oxidative stress in the rat brain. Comparison with a rational antioxidant.
Seif-El-Nasr M; Atia AS; Abdelsalam RM
Arzneimittelforschung; 2008; 58(4):160-7. PubMed ID: 18540477
[TBL] [Abstract][Full Text] [Related]
4. Emerging role of monoamine oxidase as a therapeutic target for cardiovascular disease.
Deshwal S; Di Sante M; Di Lisa F; Kaludercic N
Curr Opin Pharmacol; 2017 Apr; 33():64-69. PubMed ID: 28528298
[TBL] [Abstract][Full Text] [Related]
5. Monoamine oxidase-A, serotonin and norepinephrine: synergistic players in cardiac physiology and pathology.
Mialet-Perez J; Santin Y; Parini A
J Neural Transm (Vienna); 2018 Nov; 125(11):1627-1634. PubMed ID: 30043181
[TBL] [Abstract][Full Text] [Related]
6. Elevated monoamine oxidase a binding during major depressive episodes is associated with greater severity and reversed neurovegetative symptoms.
Chiuccariello L; Houle S; Miler L; Cooke RG; Rusjan PM; Rajkowska G; Levitan RD; Kish SJ; Kolla NJ; Ou X; Wilson AA; Meyer JH
Neuropsychopharmacology; 2014 Mar; 39(4):973-80. PubMed ID: 24154665
[TBL] [Abstract][Full Text] [Related]
7. Monoamine oxidase, monoamine oxidase inhibitors, and panic disorder.
Norman TR; Burrows GD
J Neural Transm Suppl; 1989; 28():53-63. PubMed ID: 2677243
[TBL] [Abstract][Full Text] [Related]
8. Drugs related to monoamine oxidase activity.
FiĊĦar Z
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Aug; 69():112-24. PubMed ID: 26944656
[TBL] [Abstract][Full Text] [Related]
9. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression.
Meyer JH; Ginovart N; Boovariwala A; Sagrati S; Hussey D; Garcia A; Young T; Praschak-Rieder N; Wilson AA; Houle S
Arch Gen Psychiatry; 2006 Nov; 63(11):1209-16. PubMed ID: 17088501
[TBL] [Abstract][Full Text] [Related]
10. Smoking related diseases: the central role of monoamine oxidase.
Rendu F; Peoc'h K; Berlin I; Thomas D; Launay JM
Int J Environ Res Public Health; 2011 Jan; 8(1):136-47. PubMed ID: 21318020
[TBL] [Abstract][Full Text] [Related]
11. Major depression and heart failure: Interest of monoamine oxidase inhibitors.
Corbineau S; Breton M; Mialet-Perez J; Costemale-Lacoste JF
Int J Cardiol; 2017 Nov; 247():1-6. PubMed ID: 28705604
[TBL] [Abstract][Full Text] [Related]
12. Evidence revealing deregulation of the KLF11-MAO A pathway in association with chronic stress and depressive disorders.
Harris S; Johnson S; Duncan JW; Udemgba C; Meyer JH; Albert PR; Lomberk G; Urrutia R; Ou XM; Stockmeier CA; Wang JM
Neuropsychopharmacology; 2015 May; 40(6):1373-82. PubMed ID: 25502632
[TBL] [Abstract][Full Text] [Related]
13. Subchronic glucocorticoids, glutathione depletion and a postpartum model elevate monoamine oxidase a activity in the prefrontal cortex of rats.
Raitsin S; Tong J; Kish S; Xu X; Magomedova L; Cummins C; Andreazza AC; Scola G; Baker G; Meyer JH
Brain Res; 2017 Jul; 1666():1-10. PubMed ID: 28435083
[TBL] [Abstract][Full Text] [Related]
14. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
Youdim MB; Bakhle YS
Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S287-96. PubMed ID: 16402116
[TBL] [Abstract][Full Text] [Related]
15. Greater monoamine oxidase a binding in perimenopausal age as measured with carbon 11-labeled harmine positron emission tomography.
Rekkas PV; Wilson AA; Lee VW; Yogalingam P; Sacher J; Rusjan P; Houle S; Stewart DE; Kolla NJ; Kish S; Chiuccariello L; Meyer JH
JAMA Psychiatry; 2014 Aug; 71(8):873-9. PubMed ID: 24898155
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review.
Manzoor S; Hoda N
Eur J Med Chem; 2020 Nov; 206():112787. PubMed ID: 32942081
[TBL] [Abstract][Full Text] [Related]
17. Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload.
Kaludercic N; Takimoto E; Nagayama T; Feng N; Lai EW; Bedja D; Chen K; Gabrielson KL; Blakely RD; Shih JC; Pacak K; Kass DA; Di Lisa F; Paolocci N
Circ Res; 2010 Jan; 106(1):193-202. PubMed ID: 19910579
[TBL] [Abstract][Full Text] [Related]
18. Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases.
Youdim MBH
J Neural Transm (Vienna); 2018 Nov; 125(11):1719-1733. PubMed ID: 30341696
[TBL] [Abstract][Full Text] [Related]
19. Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease.
Garcia-Miralles M; Ooi J; Ferrari Bardile C; Tan LJ; George M; Drum CL; Lin RY; Hayden MR; Pouladi MA
Exp Neurol; 2016 Apr; 278():4-10. PubMed ID: 26825854
[TBL] [Abstract][Full Text] [Related]
20. Role of Monoamine Oxidase Activity in Alzheimer's Disease: An Insight into the Therapeutic Potential of Inhibitors.
Behl T; Kaur D; Sehgal A; Singh S; Sharma N; Zengin G; Andronie-Cioara FL; Toma MM; Bungau S; Bumbu AG
Molecules; 2021 Jun; 26(12):. PubMed ID: 34207264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
